He is expected to become Representative Executive Officer, President and Chief Executive at the AGM in June
Japanese biopharmaceutical firm Sosei Group will have a new Chief Operating Officer (COO) from 1 April.
From next week, Peter Bains will assume responsibility for all operational activities of Sosei and will report to Shinichi Tamura in his ongoing capacity as Group Chairman, President and Chief Executive Officer (CEO). It is expected that Bains will become Representative Executive Officer, President and Chief Executive Officer (CEO) upon approval by the Board of Directors following Sosei Group’s Annual General Meeting in June. At the same time, Tamura is expected to become Representative Executive Officer and Executive Chairman.
Bains has nearly 30 years of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments. He had a 23-year career at GlaxoSmithKline, where he held multiple senior roles including General Manager of China, VP of International Business Development, Head of Global Marketing and Senior VP of International Commercial Development.
Since 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies. He currently serves as an Non-executive Director at Sosei Group, and as CEO at Syngene, a subsidiary of biotechnology company Biocon.
Bains said: 'Sosei Group is now at a very dynamic point in its history as it seeks to expand its operational scope and scale, and I am looking forward to contributing to its rapid evolution into a truly global biopharmaceutical company.'